D. Western Therapeutics Institute, Inc. (4576) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

RaQualia Pharma, Inc.

Wakamoto Pharmaceutical Co., Ltd.

Solasia Pharma KK

Nippon Chemiphar Co., Ltd.

Pharmarise Holdings Corp.

Renascience, Inc.

SymBio Pharmaceuticals Ltd.

D. Western Therapeutics Institute, Inc.

CanBas Co., Ltd.

BrightPath Biotherapeutics Co., Ltd.

Delta-Fly Pharma, Inc.

Why is D. Western Therapeutics Institute, Inc. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

The company has declared negative results for the last 16 consecutive quarters

INVENTORY TURNOVER RATIO(HY) Lowest at 0.57 times
DEBTORS TURNOVER RATIO(HY) Lowest at 2.71 times
NET SALES(Q) Lowest at JPY 15.11 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -46.51%, its profits have risen by 48.6%

Below par performance in long term as well as near term

Along with generating -46.51% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is D. Western Therapeutics Institute, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

D. Western Therapeutics Institute, Inc.

-46.51%

-0.35

67.25%

Japan Nikkei 225

85.83%

3.09

27.80%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.74%

EBIT Growth (5y)

-180.27%

EBIT to Interest (avg)

-152.17

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.63

Sales to Capital Employed (avg)

0.24

Tax Ratio

0.14%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.82

EV to EBIT

-7.07

EV to EBITDA

-7.66

EV to Capital Employed

13.26

EV to Sales

11.31

PEG Ratio

Dividend Yield

ROCE (Latest)

-187.36%

ROE (Latest)

-44.03%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

NET PROFIT(HY)

Higher at JPY -310.17 MM

ROCE(HY)

Highest at -56.38%

RAW MATERIAL COST(Y)

Fallen by -19.57% (YoY

-27What is not working for the Company

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.57 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.71 times

NET SALES(Q)

Lowest at JPY 15.11 MM

INTEREST(Q)

Highest at JPY 3.2 MM

OPERATING PROFIT(Q)

Lowest at JPY -166.11 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -1,099.09 %

Here's what is working for D. Western Therapeutics Institute, Inc.

Net Profit

Higher at JPY -310.17 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Raw Material Cost

Fallen by -19.57% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for D. Western Therapeutics Institute, Inc.

Net Sales

At JPY 15.11 MM has Fallen at -84.4%

over average net sales of the previous four periods of JPY 96.91 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Interest

At JPY 3.2 MM has Grown at 16.81%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales

Lowest at JPY 15.11 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (JPY MM)

Interest

Highest at JPY 3.2 MM

in the last five periods and Increased by 16.81% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Operating Profit

Lowest at JPY -166.11 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (JPY MM)

Operating Profit Margin

Lowest at -1,099.09 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Inventory Turnover Ratio

Lowest at 0.57 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 2.71 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio